Drug Combination Details
| General Information of the Combination (ID: C01361) | |||||
|---|---|---|---|---|---|
| Name | Dicoumarol NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Bladder cancer
[ICD-11: 2C94]
|
Investigative | [1] | ||
|
Prostate cancer
[ICD-11: 2C82]
|
Investigative | [1] | |||
|
Renal cell carcinoma
[ICD-11: 2C90]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | p105 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Caki | Clear cell renal cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Dicoumarol showed sensitizing effect of on TRAIL-mediated apoptosis. | |||||
| Experiment 2 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Phosphorylation | TP53 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | RT-112 | CVCL_1670 | Bladder carcinoma | Homo sapiens | ||
| 253J | CVCL_7935 | Bladder carcinoma | Homo sapiens | |||
| J82 | CVCL_0359 | Bladder carcinoma | Homo sapiens | |||
| UM-UC-3 | CVCL_1783 | Bladder carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Dicoumarol could enhance cytotoxicity of CDDP in urogenital cancer cells with wild-type p53 through the p53/p21/JNK pathways. | |||||
